Abstract: Evasion of apoptosis is a fundamental hallmark of cancer, often driven by the overexpression of anti-apoptotic B-cell lymphoma 2 (Bcl-2) family proteins. ABT-737 is a pioneering, rationally designed small-molecule inhibitor that functions as a BH3-mimetic. By binding with high affinity to the hydrophobic grooves of Bcl-2, Bcl-xL, and Bcl-w, ABT-737 displaces pro-apoptotic proteins, thereby restoring the intrinsic apoptotic pathway in malignant cells. Preclinical studies have demonstrated its efficacy across various malignancies, including non-small cell lung carcinoma (NSCLC), small cell lung cancer (SCLC), pediatric hepatoblastoma (HB), head and neck squamous cell carcinoma (HNSCC), and adult T-cell leukemia/lymphoma (ATLL). While its single-agent activity can be limited by resistance factors such as Mcl-1 overexpression, ABT-737 exhibits profound synergistic effects when combined with conventional chemotherapy, radiation, and targeted therapies. Despite its promising anti-tumor activity, the clinical translation of ABT-737 has been hindered by its lack of oral bioavailability and dose-limiting thrombocytopenia, an on-target toxicity resulting from Bcl-xL inhibition in platelets. Nevertheless, the development of ABT-737 established a critical proof-of-concept that led to the creation of next-generation, orally bioavailable, and target-specific BH3-mimetics such as ABT-263 (Navitoclax) and ABT-199 (Venetoclax).
1. Introduction
The evasion of programmed cell death, or apoptosis, is a primary mechanism by which tumor cells survive and acquire resistance to conventional anticancer therapies [3]. The Bcl-2 family of proteins plays a central role in regulating the intrinsic apoptotic pathway. In many cancers, the delicate balance between pro-apoptotic (e.g., Bax, Bak, Bim) and anti-apoptotic (e.g., Bcl-2, Bcl-xL, Mcl-1) proteins is disrupted, typically through the upregulation of anti-apoptotic members [1][3]. To counteract this, therapeutic strategies have focused on developing small-molecule inhibitors that antagonize these pro-survival proteins. In 2005, Oltersdorf et al. reported the discovery of ABT-737, a highly potent, synthetic small molecule designed to mimic the BH3 domain of pro-apoptotic proteins [3][6][9]. As a first-in-class BH3-mimetic, ABT-737 provided critical preclinical evidence that targeting the Bcl-2 family could effectively induce tumor regression in solid and hematological malignancies, marking a paradigm shift in targeted oncology [6][9].
2. Pharmacological Activity
ABT-737 has demonstrated broad pharmacological activity across a variety of cancer models. As a single agent, it has shown notable efficacy in hematological malignancies, such as adult T-cell leukemia/lymphoma (ATLL), where it induces significant tumor regression and improves survival in xenograft models [5]. It is also highly active against small cell lung cancer (SCLC) cell lines [1][3]. In solid tumors, however, its single-agent activity is often moderate, but it acts as a potent sensitizer when combined with other therapeutic modalities [1][3].
In pediatric hepatoblastoma (HB), ABT-737 significantly potentiates the efficacy of established chemotherapeutic drugs like paclitaxel, cisplatin, and doxorubicin, allowing for potential dose reductions that could minimize severe side effects such as nephrotoxicity and ototoxicity [1]. Furthermore, ABT-737 reduces the adhesion of HB cells to extracellular matrix proteins and inhibits cell migration, suggesting a role in preventing tumor metastasis [1]. In non-small cell lung carcinoma (NSCLC), ABT-737 improves radiosensitivity and drastically increases cell death when combined with EGFR tyrosine kinase inhibitors (TKIs) like erlotinib, particularly in tumors harboring EGFR kinase domain mutations [2][4]. It also synergizes with conventional chemotherapeutics in head and neck squamous cell carcinoma (HNSCC) [7] and with MEK/BRAF inhibitors in KRAS- and BRAF-mutant cancers by converting cytostatic responses into cytotoxic tumor regression [3].
3. Molecular Mechanism of Action
ABT-737 functions by mimicking the BH3 domain of pro-apoptotic proteins. It binds with high affinity to the hydrophobic groove of specific anti-apoptotic proteins, namely Bcl-2, Bcl-xL, and Bcl-w [2][3]. In cancer cells, pro-apoptotic proteins like Bax, Bak, and Bim are often sequestered and neutralized by these anti-apoptotic proteins. When ABT-737 occupies the hydrophobic groove, it competitively displaces the bound BH3-containing pro-apoptotic proteins [2][3].
Once liberated, Bax and Bak oligomerize and induce mitochondrial outer membrane permeabilization. This leads to the release of cytochrome c into the cytosol, the activation of caspase-9 and caspase-3, the cleavage of poly (ADP-ribose) polymerase (PARP), and ultimately, the execution of apoptosis [2][3][4]. Additionally, ABT-737 has been shown to upregulate the expression of Noxa, a pro-apoptotic protein, which further contributes to cell death; silencing Noxa via small interfering RNA attenuates ABT-737-induced apoptosis [2][4]. Notably, ABT-737 exhibits low affinity for other anti-apoptotic family members, such as Mcl-1, Bcl-B, and A1 (Bfl-1), which dictates its specific spectrum of activity [1][3].
4. Structure-Activity Relationship (SAR)
The discovery and optimization of ABT-737 represent a landmark achievement in fragment-based drug discovery. Researchers at Abbott Laboratories utilized a technique known as "SAR by NMR" (Structure-Activity Relationship by Nuclear Magnetic Resonance) to screen chemical libraries for small molecular fragments that could bind to the hydrophobic groove of the Bcl-xL protein [3][9].
The Bcl-xL binding site was divided into distinct pockets. The screening identified two small chemical compounds: a modified compound I that entered the P2 binding pocket, and a compound II that entered the P4 pocket [9]. By chemically linking these proximal fragments that bound to different sites within the hydrophobic groove, the researchers synthesized lead compounds with exponentially increased binding affinities. The final optimized molecule, ABT-737, binds with sub-nanomolar affinity (Ki < 1 nM) to Bcl-xL, as well as to the structurally homologous Bcl-2 and Bcl-w proteins [3][9]. Because Mcl-1 and A1 possess less homologous structures in their binding grooves, ABT-737 cannot effectively bind or inhibit them [3].
5. Current Limitations
Despite its potent preclinical efficacy, the clinical advancement of ABT-737 has been severely restricted by two major limitations. First, ABT-737 is not orally bioavailable, which complicates its dosing regimens, particularly for chronic cancer therapy [3]. Second, and more critically, ABT-737 causes dose-limiting thrombocytopenia [2][4][6]. This adverse effect is an on-target toxicity resulting from the drug's high affinity for Bcl-xL. Mature platelets rely heavily on Bcl-xL as a molecular clock for their survival; thus, the inhibition of Bcl-xL by ABT-737 triggers rapid, programmed anuclear cell death in platelets, leading to severe platelet depletion [3][6][9].
Furthermore, intrinsic or acquired resistance to ABT-737 frequently occurs in tumors that express high levels of Mcl-1. Because ABT-737 cannot inhibit Mcl-1, this protein acts as a functional substitute for Bcl-2 and Bcl-xL, sequestering the pro-apoptotic proteins (like Bax and Bak) that are displaced by ABT-737 and thereby preventing apoptosis [1][3].
6. Future Perspectives
The mechanistic insights and structural framework provided by ABT-737 have paved the way for the development of next-generation BH3-mimetics. To address the lack of oral bioavailability, ABT-263 (Navitoclax) was developed, maintaining a similar target profile but allowing for oral administration [3][6][9]. To overcome the dose-limiting thrombocytopenia caused by Bcl-xL inhibition, the molecule was further re-engineered to create ABT-199 (Venetoclax), a highly selective Bcl-2 inhibitor that spares platelets and has achieved regulatory approval for various hematological malignancies [3][6][9].
For solid tumors, where Bcl-xL often plays a more dominant role in survival than Bcl-2, future strategies involve the careful, stratified use of Bcl-xL inhibitors (such as WEHI-539 or optimized derivatives) or the use of dual inhibitors with manageable dosing schedules [3][6]. Additionally, overcoming Mcl-1-mediated resistance is a major focus. Combining BH3-mimetics with Mcl-1 specific inhibitors (e.g., S63845), or with agents that downregulate Mcl-1 expression (such as PI3K/mTOR inhibitors or epigenetic modulators), represents a highly promising rational combination strategy to achieve synergistic tumor eradication in refractory cancers [2][3][6].
